肝内胆管结石
代谢组学
代谢物
色谱法
代谢组
化学
串联质谱法
接收机工作特性
内科学
医学
作者
Cong Wang,Jun Yang,Enliang Li,Shuaiwu Luo,Chi Sun,Yuting Liao,Min Li,Jin Ge,Jun Lei,Fan Zhou,Linquan Wu,Wenjun Liao
出处
期刊:Metabolomics
[Springer Nature]
日期:2022-08-17
卷期号:18 (9)
标识
DOI:10.1007/s11306-022-01927-2
摘要
Background & aimsA metabolomic study of hepatolithiasis has yet to be performed. The purpose of the present study was to characterize the metabolite profile and identify potential biomarkers of hepatolithiasis using a metabolomic approach.MethodsWe comprehensively analyzed the serum metabolites from 30 patients with hepatolithiasis and 20 healthy individuals using ultra-high performance liquid chromatography-tandem mass spectrometry operated in negative and positive ionization modes. Statistical analyses were performed using univariate (Student’s t-test) and multivariate (orthogonal partial least-squares discriminant analysis) statistics and R language. Receiver operator characteristic (ROC) curve analysis was performed to identify potential predictors of hepatolithiasis.ResultsWe identified 277 metabolites that were significantly different between hepatolithiasis serum group and healthy control serum group. These metabolites were principally lipids and lipid-like molecules and amino acid metabolites. The steroid hormone biosynthesis pathway was enriched in hepatolithiasis serum group. In all specific metabolites, 75 metabolites were over-expressed in hepatolithiasis serum group. The AUC values for 60 metabolites exceeded 0.70, 4 metabolites including 18-β-Glycyrrhetinic acid, FMH, Rifampicin and PC (4:0/16:2) exceeded 0.90.ConclusionsWe have identified serum metabolites that are associated with hepatolithiasis for the first time. 60 potential metabolic biomarkers were identified, 18-β-Glycyrrhetinic acid, FMH, Rifampicin and PC (4:0/16:2) may have the potential clinical utility in hepatolithiasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI